



For immediate release 2.00pm: 14 December 2017

HVIVO PLC
("hVIVO" or the "Company")

Director's Dealings

hVIVO plc (AIM: HVO), a specialty biopharma company with discovery and clinical testing capabilities, announces that Dr Trevor Phillips, Executive Chairman of the Company, today purchased 9,035 Ordinary Shares of 5 pence each in the Company ("Ordinary Shares") at a price of 56.0 pence per share.

Following this transaction, Dr Phillips' total interest in the Company is 9,035 Ordinary Shares, representing approximately 0.01% of the Company's issued share capital.

The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further detail:

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

1	Details of the persons discharging managerial responsibilities/persons closely associated	
a)	Name	Dr Trevor Phillips
2	Reason for the notification	
a)	Position/ status	Executive Chairman
b)	Initial notification/ Amendment	Initial Notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor	
a)	Name	hVIVO plc
b)	Legal Entity Identifier	N/A
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted	
a)	Description of the financial instrument, type of instrument	Ordinary shares of 5 pence each
	Identification code	GB00B6ZM0X53

b)	Nature of the transaction	Acquisition of ordinary shares		
c)	Currency	GBP		
d)	Price(s) and volume(s)	Director	Price (p)	Volume
		Dr Trevor Phillips	56.0	9,035
e)	Aggregated information			
	- Aggregated volume	9,035		
	- Price	56.0p		
	- Aggregated total	£5,059.60		
f)	Date of the transaction	14 December 2017		
g)	Place of the transaction	London Stock Exchange, AIM		

For further information please contact:

hVIVO plc +44 207 756 1300
Kym Denny (Chief Executive Officer)
Graham Yeatman (Chief Financial & Business Officer)

Media Enquiries +1 919 710 9658
Susan Flood (Head of Marketing)

Numis Securities Limited +44 207 260 1000
Michael Meade / Freddie Barnfield (Nominated Adviser)
James Black / Michael Burke (Corporate Broking)

FTI Consulting
Simon Conway / Victoria Foster Mitchell (UK) +44 203 727 1000
John Capodanno / Evan Smith (US) +1 212 850 5705

Notes to Editors:

hVIVO plc ("hVIVO"), a specialty biopharma company with discovery and clinical testing capabilities, is pioneering a human-based analytical platform to accelerate drug discovery and development in respiratory and infectious diseases. Leveraging human disease models in flu, RSV and asthma exacerbation, the hVIVO platform captures disease in motion, illuminating the entire disease life cycle from healthy to sick and back to health. Based in the UK, market leader hVIVO has conducted more than 50 clinical studies, inoculated over 2500 volunteers and has three first-in-class therapies currently in development with a growing pre-clinical pipeline.